Biomarkers for Prognostication After Acute Coronary Syndromes. New Times and Statistics

Journal of the American College of Cardiology

Volumn 54, Issue 4, 2009, Pages 365-367

  deFilippi, Christopher R ^a   Seliger, Stephen L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

acute coronary syndrome; biomarkers; risk assessment; stable coronary artery disease

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; TROPONIN;

ACUTE CORONARY SYNDROME; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; EDITORIAL; HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RISK FACTOR; SCORING SYSTEM;

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 67650164733     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.04.031     Document Type: Editorial

References (19)

1. Morrow D.A., and Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 108 (2003) 250-252
2. Morrow D.A., Cannon C.P., Jesse R.L., et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 115 (2007) e356-e375
3. Jernberg T., Lindahl B., James S., Larsson A., Hansson L.O., and Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 110 (2004) 2342-2348
4. Morrow D.A., Sabatine M.S., Brennan M.L., et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 29 (2008) 1096-1102
5. Sabatine M.S., Morrow D.A., de Lemos J.A., Jarolim P., and Braunwald E. Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur Heart J 30 (2009) 162-169
6. Sabatine M.S., Morrow D.A., Higgins L.J., et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117 (2008) 1936-1944
7. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105 (2002) 1760-1763
8. Westerhout C.M., Fu Y., Lauer M.S., et al. Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers. J Am Coll Cardiol 48 (2006) 939-947
9. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol 50 (2007) e1-e157
10. Scirica B.M., Morrow D.A., Cannon C.P., et al. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem 53 (2007) 1800-1807
11. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
12. Lindahl B., Lindback J., Jernberg T., et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol 45 (2005) 533-541
13. Zethelius B., Berglund L., Sundstrom J., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358 (2008) 2107-2116
14. Eggers K.M., Lagerqvist B., Venge P., Wallentin L., and Lindahl B. Persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts long-term mortality. Circulation 116 (2007) 1907-1914
15. Morrow D.A., de Lemos J.A., Blazing M.A., et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 294 (2005) 2866-2871
16. Eggers K.M., Lagerqvist B., Venge P., Wallentin L., and Lindahl B. Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 54 (2009) 357-364
17. Pencina M.J., D'Agostino Sr. R.B., D'Agostino Jr. R.B., and Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27 (2008) 157-172 discussion 207-12
18. Cook N.R. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115 (2007) 928-935
19. Ridker P.M., Paynter N.P., Rifai N., Gaziano J.M., and Cook N.R. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 118 (2008) 2243-2251